Lv56
1538 积分 2025-03-04 加入
Correction to "Closing the Design-Make-Test-Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability"
26天前
已完结
Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs
1个月前
已完结
Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating Profiles
1个月前
已完结
Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?
1个月前
已关闭
Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability
1个月前
已完结
Correction to "Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment"
2个月前
已完结
Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014
2个月前
已完结
Risk of Enzyme- and Transporter-mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews
2个月前
已完结
Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications
2个月前
已完结
Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations
2个月前
已完结
皖公网安备34019202002308
